Innovation Pharmaceuticals Inc (IPIX)

[frrol]

An informative article to give perspective on Kevetrin. Loxo's drug works on a specific genetic defect (not a mutation or inactivation of our p53) and is reasonably tolerated. It is applicable to only approx 0.5% of all cancers but is showing amazing immediate efficacy in a medium-size Phase 2, though durability of effect is still uncertain. Nevertheless, the market is valuing the company's pipeline (they have an oncolytic platform) at about $1B net of the cash. Clinical results like these though are exciting, and the market responds accordingly. I'd also an example of "targeted treatment" based on the genetic profile of the tumor, which is relevant for Kevetrin. Immuno is hot now, but this approach is catching on as well.

https://www.forbes.com/sites/matthewherper/2017/06/03/a-new-cancer-drug-helped-almost-everyone-who-took-it-almost-heres-what-it-teaches-us/#794a1af6b25f